Healthy Extracts Q2 Revenue Jumps 113% but Going Concern Doubt and $5.4M Insider Loan Weigh
HYEX sits 68% above its 52-week low of $0.805 on light trading volume (0.2× avg).
Summary
Healthy Extracts reported 113% Q2 revenue growth to $2.07 million, but disclosed going concern doubt, a $5.4 million insider loan, and a new convertible note with dilutive terms.
Key Events · Earnings and Guidance · HYEX
-
Q2 Revenue Up 113%
Revenue reached $2,067,212 for Q2 2026, up from $968,656 a year earlier, driven by the Gummy USA merger and Adli Gummies acquisition.
-
Going Concern Doubt
Management states doubt about the company's ability to continue as a going concern within one year, citing neutral cash flow and an accumulated deficit of $20,450,948.
-
$5.4M Insider Share Loan
CEO Donald Swanson loaned 3,000,000 shares back to the company, recorded as a $5.4 million related-party note payable, pushing current liabilities to $8.4 million.
-
New Convertible Note
Subsequent to quarter-end, the company issued a $258,750 note to LABRYS FUND II, L.P. with net proceeds of $225,000, convertible at the lesser of $2.00 or 75% of the lowest closing bid.
Analysis · HYEX · Life Sciences
Revenue growth is strong, but the balance sheet is under pressure. Current liabilities ballooned to $8.4 million from $1.8 million at year-end, largely due to a $5.4 million related-party note from CEO Donald Swanson's share loan. Management explicitly states doubt about the company's ability to continue as a going concern within one year. A subsequent $258,750 convertible note with a discount-to-market conversion feature adds dilution risk. The material weakness in internal controls remains unresolved.
At the time of this filing, HYEX was trading at $1.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $19.9M. The 52-week trading range was $0.81 to $4.29. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.